NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Dr Ashkan is a co-author on this just published comprehensive study in 'Neuro-Oncology', on the increasing incidence of primary brain tumours in England (not all of UK). It is the most up-to-date study of its kind (at least for England).
'Neuro-Oncology' is the official journal of SNO.

"The age-standardized incidence for glioblastoma increased from 3.27 per 100 000 population per year in 1995 to 7.34 in men in 2013 and from 2.00 to 4.45 in women."

The article gives a full breakdown of brain tumour types, and is an interesting read for GBM background information.

They conclude:-

"Results show an overall rise in the incidence rate of these tumors being diagnosed in England between 1995 and 2017. While the incidence varied for the different brain tumor subtypes, the most common brain tumors—glioblastoma and meningioma—seem to be driving this overall increase. Explanations for the increase in the number of primary brain tumors are likely to include aging of the population, improvements in access to neurosurgical care and diagnostic tools, and more complete and detailed records, including benign tumors, reaching NCRAS as a result of the regular updates in the coding of the WHO classification for CNS tumors. All these factors are likely to play a role in contributing to the incidence of brain tumors, particularly for glioblastomas and meningiomas."

I reckon they could have given consideration to other factors such ionising / EMF radiation, but that would have required a different type of technical analysis.

Seems a bit callous to think in terms of GBM 'market size'.
But suffice to say, it sure isn't shrinking.

https://academic.oup.com/neuro-oncology/article/23/8/1371/6218679